Trastuzumab beyond progression in HER2-positive metastatic breast cancer

被引：1
作者：
Al-Naqqash, Manwar [1 ,2 ]
Jasim Al-Serarati, Waleed [3 ]
Farooq Kareem, Tara [4 ]
机构：
[1] Univ Baghdad, Dept Surg, Coll Med, Baghdad 10001, Iraq
[2] Minist Hlth Environm, Dept Radiat Oncol, Oncol Teaching Hosp, Baghdad Med City Complex, Baghdad, Iraq
[3] Minist Hlth & Environm, Dept Oncol, Baghdad Med City Complex, Baghdad, Iraq
[4] Minist Hlth & Environm, Oncol Teaching Hosp, Dept Diagnost Radiol, Baghdad Med City Complex, Baghdad, Iraq
来源：
BREAST JOURNAL | 2021年 / 27卷 / 03期
关键词：
breast cancer; HER2; neu; time to progression; trastuzumab;
D O I：
10.1111/tbj.14157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：297 / 299
页数：3
相关论文
共 50 条
  • [1] Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond
    Perez, Jose
    Garrigos, Laia
    Gion, Maria
    Janne, Pasi A.
    Shitara, Kohei
    Siena, Salvatore
    Cortes, Javier
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 811 - 824
  • [2] Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
    R Y Tsang
    R S Finn
    British Journal of Cancer, 2012, 106 : 6 - 13
  • [3] Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
    Tsang, R. Y.
    Finn, R. S.
    BRITISH JOURNAL OF CANCER, 2012, 106 (01) : 6 - 13
  • [4] Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
    Dogan, Izzet
    Aydin, Esra
    Khanmammadov, Nijat
    Paksoy, Nail
    Saip, Pinar
    Aydiner, Adnan
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [5] Role of trastuzumab in the management of HER2-positive metastatic breast cancer
    Milani, Andrea
    Montemurro, Filippo
    Gioeni, Luisa
    Aglietta, Massimo
    Valabrega, Giorgio
    BREAST CANCER-TARGETS AND THERAPY, 2010, 2 : 93 - 109
  • [6] HER2-Positive Breast Cancer: Beyond Trastuzumab
    Murphy, Conleth G.
    Fornier, Monica
    ONCOLOGY-NEW YORK, 2010, 24 (05): : 410 - 415
  • [7] Beyond trastuzumab: New treatment options for HER2-positive breast cancer
    Saini, Kamal S.
    Azim, Hatem A., Jr.
    Metzger-Filho, Otto
    Loi, Sherene
    Sotiriou, Christos
    de Azambuja, Evandro
    Piccart, Martine
    BREAST, 2011, 20 : S20 - S27
  • [8] Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience
    Waddell, T.
    Kotsori, A.
    Constantinidou, A.
    Yousaf, N.
    Ashley, S.
    Parton, M.
    Allen, M.
    Starling, N.
    Papadopoulos, P.
    O'Brien, M.
    Smith, I.
    Johnston, S.
    BRITISH JOURNAL OF CANCER, 2011, 104 (11) : 1675 - 1679
  • [9] Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab
    Gradishar, W. J.
    ANNALS OF ONCOLOGY, 2013, 24 (10) : 2492 - 2500
  • [10] Paclitaxel, carboplatin, and trastuzumab in HER2-positive metastatic breast cancer
    Andrew D. Seidman
    Larry Norton
    Current Oncology Reports, 2005, 7 (1) : 9 - 11
12345